describ
design
synthesi
biolog
evalu
seri
molecul
toward
develop
novel
peptidomimet
inhibitor
sarscov
pro
dock
studi
involv
bind
initi
lead
compound
sarscov
pro
motiv
replac
thiazol
benzothiazol
unit
warhead
moieti
site
modif
led
identif
potent
deriv
includ
ic
k
valu
submicromolar
nanomolar
rang
particular
compound
exhibit
potent
inhibitori
activ
k
valu
nm
respect
peptidomimet
compound
identifi
process
attract
lead
develop
potenti
therapeut
agent
sar
structur
requir
peptidomimet
potent
inhibitori
activ
sarscov
pro
may
summar
follow
presenc
benzothiazol
warhead
posit
ii
hydrogen
bond
capabl
cyclic
lactam
iii
appropri
stereochemistri
hydrophob
moieti
size
iv
uniqu
fold
conform
assum
phenoxyacetyl
moieti
j
u
r
n
l
h
e
p
g
e
w
w
w
e
l
e
v
e
r
c
l
c
e
b
c
pocket
larger
size
thiazol
unit
ntermin
protrud
bind
site
fig
thu
sequenti
optim
stepbystep
approach
involv
test
wide
varieti
substructur
substitut
focus
parallel
result
analog
identifi
exhibit
potent
inhibitori
activ
submicromolar
nanomolar
rang
describ
result
extens
studi
detail
includ
design
synthesi
molecular
model
biolog
evalu
seri
sarscov
pro
inhibitor
pro
inhibitor
gener
synthes
assembl
two
key
fragment
dipeptid
ctermin
thiazol
deriv
dipeptid
prepar
via
fmocbas
solidphas
peptid
synthesi
wang
resin
correspond
fmocamino
acid
introduc
onto
resin
via
diisopropylcarbodiimid
dic
mediat
coupl
presenc
catalyt
amount
n
dimethylaminopyridin
dmap
dmf
scheme
result
intermedi
treat
piperidin
dmf
remov
fmocgroup
coupl
fmocvalin
yield
via
dichobt
method
dmf
fmocdeprotect
reaction
variou
carboxyl
acid
acid
chlorid
produc
crucial
dipeptid
treatment
resin
trifluoroacet
acidwat
h
dipeptid
use
directli
next
step
without
purif
synthes
key
intermedi
path
thiazol
well
titl
inhibitor
indic
scheme
optic
pure
glutam
acid
ester
convert
clactamacid
treatment
bromoacetonitril
follow
reduct
pto
cycliz
hydrolysi
coupl
n
odimethylhydroxylamin
via
hobt
method
yield
weinreb
amid
weinreb
amid
coupl
appropri
thiazol
presenc
nbutyl
lithium
nbuli
lithium
diisopropylamid
lda
afford
thiazol
deprotect
subsequ
react
dipeptid
presenc
obenzotriazolen
n
n
n
tetramethyluroniumhexafluoro
phosphat
hbtu
hobt
dipea
dmf
afford
titl
compound
sever
acut
respiratori
syndrom
sar
typic
form
pneumonia
first
report
southern
china
novemb
sar
rapidli
spread
countri
creat
panic
among
public
world
health
organ
initi
outbreak
sar
includ
individu
diagnos
diseas
live
claim
sar
character
high
fever
malais
headach
rigor
nonproduct
cough
caus
agent
sar
identifi
novel
human
coronaviru
sarscov
encod
sever
viral
proteas
proteolyz
polyprotein
yield
function
protein
one
highli
conserv
cystein
proteas
main
proteas
pro
also
known
dimer
chymotrypsinlik
proteas
pro
pro
mediat
major
proteolyt
process
involv
produc
two
larg
viral
polyprotein
replicas
activ
site
sarscov
pro
contain
togeth
constitut
catalyt
dyad
cystein
moieti
function
common
nucleophil
proteolyt
process
sinc
sarscov
pro
play
import
role
viru
life
cycl
recogn
key
target
discoveri
antisar
agent
numer
sarscov
pro
inhibitor
identifi
chemic
librari
screen
ration
design
approach
base
activ
site
properti
proteas
inhibitor
includ
peptidomimet
acid
deriv
bifunct
arylboron
acid
ketoglutamin
deriv
isatin
deriv
zinc
conjug
compound
cinanserin
calmodulin
benzotriazol
bunsatur
acid
anilid
glutam
acid
glutamin
peptid
possess
trifluoromethyl
keton
group
ongo
effort
develop
antisar
agent
previous
identifi
seri
zvalleuala
sarscov
pro
inhibitor
among
compound
compound
fig
identifi
potent
lead
compound
k
valu
lm
primari
structureact
relationship
sar
studi
reveal
presenc
rigid
cyclic
amid
electronwithdraw
chemic
warhead
moieti
import
inhibitori
activ
present
studi
perform
molecular
model
studi
involv
pro
studi
reveal
presenc
space
tabl
imidazoletyp
compound
prepar
indic
scheme
anoth
key
imidazol
thiazol
prepar
commerci
avail
bochi
to
oh
use
reaction
condit
indic
prepar
clactam
thiazol
tosylprotect
success
convert
imidazoletyp
analog
via
deprotect
coupl
chemistri
describ
prepar
abil
synthet
compound
inhibit
proteas
activ
sarscov
pro
evalu
briefli
ic
valu
inhibitor
assess
appar
decreas
substrat
htsavlqsgfrknh
digest
sar
pro
describ
previous
cleavag
reaction
monitor
analyt
hplc
cleavag
rate
calcul
decreas
substrat
peak
area
determin
kinet
paramet
constant
substrat
concentr
differ
inhibitor
concentr
assess
k
valu
initi
rate
measur
determin
previous
describ
use
fluorescencebas
peptid
cleavag
assay
fluorogen
substrat
dabcylktsavlqsgfrkmeedan
rate
substrat
cleavag
detect
increas
fluoresc
time
see
section
tabl
report
ic
andor
k
valu
mean
independ
experi
previou
report
inhibitor
found
moder
sarscov
pro
inhibitor
ic
valu
lm
k
valu
lm
first
attempt
investig
effect
ntermin
substitu
activ
profil
tabl
inhibitori
activ
seri
aromat
aliphat
carbam
evalu
none
compound
show
inhibitori
potenc
compar
result
obtain
acyl
deriv
interestingli
deriv
ic
lm
phenoxymethyl
carbonyl
display
slightli
higher
activ
thu
presenc
phenoxymethyl
carbonyl
ntermin
posit
appear
enhanc
activ
molecular
model
studi
involv
pro
enzym
fig
provid
insight
understand
bind
inhibitor
activ
site
enzym
see
section
fig
introduct
spaciou
warhead
group
suggest
mean
increas
inhibitori
activ
therefor
modifi
inhibitor
includ
larger
unit
benzothiazol
seri
thiazol
posit
compound
bear
display
lower
inhibitori
activ
ic
lm
compound
bear
benzothiazol
exhibit
fourto
fivefold
higher
activ
ic
lm
ic
lm
higher
activ
notabl
exhibit
potent
inhibit
k
valu
nm
find
strongli
suggest
benzothiazol
unit
suitabl
chemic
warhead
group
occupi
site
subsequ
studi
inhibitor
advanc
lead
compound
optim
seri
electrondon
electronwithdraw
substitu
introduc
onto
phenyl
ring
inde
compound
electron
donat
substitu
methoxi
hydroxyl
n
n
dimethylamino
por
mposit
p
oor
mmethoxi
respect
promis
inhibitor
mn
n
dimethylamino
deriv
k
valu
nm
howev
analog
electronwithdraw
substitu
pcarboxyl
pnitro
display
rel
low
potenc
result
strongli
suggest
electrondon
substitu
phenyl
ring
import
favor
enhanc
inhibitori
activ
pro
isoster
replac
around
context
yield
notabl
differ
inhibitori
activ
replac
phenoxi
pyridinyloxi
hamper
inhibitori
potenc
interestingli
potenc
recov
upon
phenylamino
substitut
ic
lm
chain
length
phenyl
group
contribut
significantli
inhibitor
potenc
indic
decreas
activ
analog
ic
lm
varieti
substitu
group
introduc
tabl
initi
stereochemistri
sizeappropri
amino
acid
residu
test
compound
lleucin
replac
dleucin
dramat
reduc
inhibitori
activ
replac
bulki
hydrophob
side
chain
cyclohexylmethyl
benzyl
result
solubl
issu
enzym
assay
replac
polar
glutam
acid
increas
inhibitori
potenc
lleucin
therefor
appear
provid
suitabl
stereochemistri
appropri
size
fit
result
also
well
correl
dock
studi
hydrogenbond
properti
pyrrolidon
structur
chain
studi
imidazol
moieti
shown
tabl
none
compound
exhibit
notabl
inhibitori
activ
sarscov
pro
thu
cyclic
amid
clactam
site
crucial
potent
inhibitori
activ
moieti
next
examin
vari
thiazol
tabl
inhibitori
activ
k
valu
compound
list
tabl
analog
k
nm
show
lower
activ
howev
thiazol
gener
exhibit
low
inhibitori
activ
compar
although
k
valu
inhibitor
includ
submicromolar
rang
studi
confirm
benzothiazol
unit
appropri
warhead
group
moieti
previous
demonstr
inhibitori
activ
compound
contain
thiazol
residu
insert
pocket
timedepend
suggest
revers
strong
bind
interact
proteas
examin
molecular
dock
potent
activ
compound
comparison
lead
compound
structur
similar
ligand
dock
structur
elucid
xray
crystallographi
pdb
id
k
lm
fig
sever
minim
process
perform
use
forc
field
model
solvat
environ
surround
inhibitor
molecular
simul
subsequ
perform
figur
show
moieti
yellow
stick
interact
region
enzym
lead
interestingli
benzothiazol
unit
occupi
pocket
tightli
smaller
thiazol
moieti
minim
energi
obtain
dock
studi
kcalmol
respect
addit
n
dimethylaminophenoxi
acetyl
group
adopt
uniqu
fold
conform
form
new
hydrophob
interact
acarbon
ala
site
shown
figur
describ
design
synthesi
biolog
evalu
seri
tripeptidetyp
sarscov
pro
inhibitor
sar
studi
dock
studi
initi
lead
compound
bound
sarscov
pro
provid
better
understand
inhibitoract
site
structur
interact
studi
led
develop
sever
potent
inhibitor
includ
ic
k
valu
submicromolar
nanomolar
rang
compound
exhibit
potent
inhibitori
activ
k
valu
nm
respect
result
clearli
indic
peptidomimet
promis
inhibitor
develop
potenti
therapeut
agent
sar
structur
requir
peptidomimet
display
potent
inhibitori
activ
sarscov
pro
could
summar
follow
benzothiazol
unit
effect
accommod
chemic
warhead
ii
hydrogenbond
capabl
cyclic
lactam
iii
appropri
stereochemistri
sizeappropri
lleucin
moieti
pocket
iv
uniqu
fold
conform
assum
phenoxyacetyl
moieti
experiment
reagent
solvent
purchas
wako
pure
chemic
ind
ltd
osaka
japan
aldrich
chemic
co
inc
milwauke
wi
use
without
purif
analyt
thinlay
chromatographi
tlc
perform
merck
silica
gel
precoat
plate
prepar
hplc
perform
use
reversephas
column
mm
sunfir
prep
lm
binari
solvent
system
linear
gradient
ch
cn
aqueou
tfa
flow
rate
mlmin
detect
uv
nm
solvent
use
hplc
hplcgrade
chemic
analyt
grade
better
h
c
nmr
spectra
obtain
use
jeol
mhz
spectromet
varian
mercuri
spectromet
mhz
bruker
spectromet
mhz
tetramethylsilan
intern
standard
highresolut
mass
spectra
esi
ei
record
micromass
qtof
ultima
api
jeol
jmsgcmate
spectromet
mass
spectra
esi
record
shimadzu
gener
solidphas
synthet
procedur
prepar
dipeptid
wang
resin
mmol
dmf
ml
ad
fmocamino
acid
equiv
dic
equiv
dmap
equiv
mixtur
stir
h
resin
filter
wash
dmf
ch
cl
dri
vacuum
yield
remov
fmocgroup
use
piperidin
dmf
min
next
appropri
amino
acid
coupl
resin
use
coupl
agent
dic
equiv
hobt
equiv
solidphas
synthesi
techniqu
result
intermedi
treat
piperidin
dmf
min
remov
fmocgroup
subsequ
react
correspond
carboxyl
acid
equiv
dichobt
method
acid
chlorid
equiv
presenc
et
n
produc
final
resin
treat
tfah
ml
mixtur
filter
h
filtrat
remov
high
vacuum
give
desir
dipeptid
use
directli
next
step
without
purif
analysi
compound
prepar
sequenti
reaction
wellknown
intermedi
report
previous
solut
acid
g
mmol
dmf
ml
ad
g
mmol
hobt
g
mmol
n
odimethylhydroxylamin
g
mol
ambient
temperatur
solut
cool
tea
ml
mmol
ad
slowli
h
dmf
evapor
result
residu
dissolv
ethyl
acet
ml
organ
phase
subsequ
wash
citric
acid
ml
nahco
ml
brine
ml
organ
layer
dri
na
concentr
reduc
pressur
yield
weinreb
amid
deriv
purifi
column
chromatographi
etoacmeoh
solut
thiazol
g
mmol
thf
ad
nbuli
mol
thf
ml
dropwis
min
h
stir
weinreb
amid
g
mmol
thf
slowli
ad
dropwis
min
solut
stir
h
reaction
quench
sat
nh
cl
allow
stir
min
mixtur
evapor
dissolv
ethyl
acet
solut
wash
water
brine
dri
na
organ
layer
concentr
reduc
pressur
result
residu
subject
flash
chromatographi
etoac
meoh
obtain
pure
compound
data
compound
report
previou
articl
compound
prepar
accord
procedur
describ
synthesi
compound
prepar
use
procedur
similar
describ
prepar
data
compound
report
previou
articl
cool
solut
commerci
avail
mmol
dri
thf
solut
lda
mmol
slowli
ad
h
precool
solut
weinreb
amid
dri
thf
slowli
ad
reaction
stir
h
solut
allow
warm
room
temperatur
quench
addit
water
ml
extract
ethyl
acet
ml
combin
organ
layer
dri
anhydr
na
filter
evapor
vacuo
crude
mixtur
purifi
use
flash
chromatographi
nhexaneetoac
furnish
yield
brown
solid
compound
prepar
accord
procedur
describ
synthesi
solut
mmol
thf
ml
ad
tosyl
chlorid
equiv
min
et
n
equiv
ad
slowli
allow
stir
h
condit
solvent
evapor
result
residu
dissolv
ethyl
acet
ml
organ
phase
wash
citric
acid
ml
nahco
ml
brine
ml
layer
dri
na
concentr
reduc
pressur
yield
purifi
column
chromatographi
nhexaneetoac
solut
mmol
ch
cl
ml
ad
tfah
ml
solut
stir
h
evapor
solvent
reduc
pressur
correspond
deprotect
lactam
residu
mmol
coupl
dipeptid
equiv
use
coupl
agent
hbtu
equiv
hobt
equiv
presenc
diisopropylethylamin
dipea
equiv
dmf
ml
reaction
mixtur
allow
stir
h
ambient
condit
solvent
evapor
high
vacuum
residu
dissolv
ethyl
acet
ml
organ
layer
wash
citric
acid
ml
nahco
ml
brine
ml
solut
dri
na
filter
evapor
reduc
pressur
give
compound
compound
prepar
use
procedur
similar
describ
synthesi
compound
purifi
revers
phase
hplc
initi
rate
measur
determin
previous
describ
use
fluorescencebas
peptid
cleavag
assay
commerci
avail
fluorogen
substrat
dabcylktsavlqsgfrkmeedan
genesi
biotech
chang
fluoresc
intens
monitor
cari
eclips
fluoresc
spectrophotomet
varian
nm
excit
emiss
wavelength
respect
substrat
dissolv
deioniz
water
inhibitor
dissolv
dmso
experi
perform
buffer
mm
sodium
phosphat
mm
sodium
chlorid
mm
edta
mm
tcep
dmso
ph
vari
inhibitor
concentr
lm
reaction
initi
ad
proteas
final
concentr
nm
solut
substrat
final
concentr
lm
total
volum
microcuvett
data
assay
analyz
use
nonlinear
regress
analysi
softwar
origin
